XIPERE: cost and payments to doctors
What Medicare Part D paid pharmacies for XIPERE, and the payments that named it as the associated drug or biological under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Bausch & Lomb Americas Inc.?
Bausch & Lomb Americas Inc. reported the most payments naming XIPERE. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $1.2M
- Providers
- 1,880
- Transactions
- 5,551
- Average per transaction
- $221
The per-transaction average — $221 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,880 providers the average total is $654, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Bausch & Lomb Americas Inc. | $1,113,281 | 90.6% |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | $115,676 | 9.4% |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | $6 | 0.0% |
Other products from Bausch & Lomb Americas Inc.
The company that reported the most payments naming XIPERE also reports against these.
- MIEBO$12,555,869
- XIIDRA$9,922,924
- INFUSE$8,244,628
- VYZULTA$3,949,322
- VISUDYNE$2,770,836
- enVista MX60 IOL$2,741,800
- OPHTHALMIC INSTRUMENTS$2,674,412
- STELLARIS ELITE$1,582,540
- ZENLENS$1,159,018
- Crystalens Accommodating IOL (AT-52AO)$1,142,392